A Phase 3 interventional study of Cyclosporine ophthalmic solution in Dry Eye Syndromes, sponsored by Hanlim Pharm. Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2014-09-03.
Sponsored by Hanlim Pharm. Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies testing cyclosporine in Dry Eye Syndromes — 5 open to participants now, 5 under way, none of them phase 3. Cyclosporine · Dry Eye Syndromes.
Among the 45 studies testing cyclosporine in Dry Eye Syndromes, this one is the 14th largest by enrollment of the 41 interventional ones that give a count, is one of 3 that started in 2013, is one of 7 in phase 3, and was the 17th registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.
Browse Dry Eye Syndromes studies →5 of the 45 studies testing cyclosporine in Dry Eye Syndromes are open now, in 2 countries. Recruiting first, the newest first:
Ocular Aesthetics, LLC dba Ocular Clinical Trials · Sites in United States
Ages 18+
University of Alabama at Birmingham · Sites in United States
Ages 18+
The University of New South Wales · Sites in Australia
Ages 18+
Canyon City Eyecare · Sites in United States
Ages 18+
Baylor College of Medicine
Ages 18+
By country, each count listing its studies:
Cyclosporine: first FDA approval 1983 (SANDIMMUNE), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 86 is above the median of 60 across 1,129 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 51 across the 41 interventional studies. Of the 35 that completed or were terminated, 11 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 45 have an industry lead sponsor. The 10 most frequent:
Hanlim Pharm. Co., Ltd. is the lead sponsor of 50 studies on the registry; 8 are open to participants now.
Hanlim Pharm. Co., Ltd. has 3 studies filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
5 of the studies testing cyclosporine in Dry Eye Syndromes that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06898853The University of New South WalesThe Effect of 0.1% Topical Ciclosporin A for 12-weeks on the Eye Surface Immune Cells in Dry Eyes | 2026-12-30 |
| NCT07553455Canyon City EyecareVevye + Flarex Combination Therapy for Dry Eye | 2026-12-31 |
| NCT07224529University of Alabama at BirminghamEfficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction | 2027-02-01 |
| NCT07904728Ocular Aesthetics, LLC dba Ocular Clinical TrialsTreating Contact Lens Discomfort With Cyclosporine 0.1% Ophthalmic Solution | 2027-03-15 |
| NCT07368595Baylor College of MedicineComparison of Conjunctival Goblet Cell Density in Dry Eye Patients Treated With Cyclosporine 0.1% Dissolved in Perfluorobutylpentane (Vevye®) or Generic 0.05% Cyclosporine Emulsion for 8 Weeks | 2027-03-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 45 studies testing cyclosporine in Dry Eye Syndromes, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical Study is Tisporin Eye Drops 0.05%(Cyclosporine ophthalmic solution) group and Restasis Eye Drops 0.05%(Cyclosporine ophthalmic suspension) group 12 weeks after treatment, each treatment group comparisons for evaluation of efficacy and safety in Moderate to Severe Dry Eye Disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
[Patients with moderate-to-severe ocular dry eye]
Exclusion Criteria:
The patients with systemic or ocular disorders affected the test results (ocular surgery, trauma, or disease)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cyclosporine 0.05% : 1 drop twice a day for 12 weeks to both eyes
Drug: Cyclosporine ophthalmic solution
Cyclosporine 0.05% : 1 drop twice a day for 12 weeks to both eyes
Drug: Cyclosporine ophthalmic solution
1 drop twice/day for 12 weeks to both eyes
Also known as: Restasis Eye Drops, Tisporin Eye Drops
Corneal staining test
Time frame: 12 weeks
Corneal staining test
Time frame: 4, 8 weeks
Ocular surface disease index (OSDI)
Time frame: 4, 8, 12 weeks
Tear break up time (TBUT)
Time frame: 4, 8, 12 weeks
Non-anesthetic Schirmer test
Time frame: 4, 8, 12 weeks
Conjunctival staining
Time frame: 4, 8, 12 weeks
The record gives a start of Dec 2013, a primary completion of Apr 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cyclosporine